文献速递心力衰竭与心肌病

利钠肽在门诊慢性射血分数保留心衰评估中的循证应用

Evidence-Based Application of Natriuretic Peptides in the Evaluation of Chronic Heart Failure With Preserved Ejection Fraction in the Ambulatory Outpatient Setting.
PubMed 文献 · Circulation · 2025-01-22

研究在慢性呼吸困难患者中,以运动导管检查等客观标准确诊HFpEF,推导并验证按肥胖和房颤分层的NT-proBNP诊断界值。结果显示现行排除阈值<125 pg/mL在BMI≥35 kg/m2时敏感性不足,而<50 pg/mL敏感性良好;纳入阈值≥500 pg/mL特异性高,BMI≥35 kg/m2时可用≥220 pg/mL;房颤患者中NT-proBNP几乎无额外鉴别价值。

要点

  • 现行排除阈值<125 pg/mL在BMI≥35 kg/m2时敏感性仅67%,建议改用<50 pg/mL。
  • 纳入阈值≥500 pg/mL特异性85%,BMI≥35 kg/m2时可用≥220 pg/mL。
  • 房颤合并呼吸困难者≥98%为HFpEF,NT-proBNP无额外鉴别价值。

核心结论

  • 现行NT-proBNP纳入和排除阈值在慢性不明原因呼吸困难患者中错误率高,且受肥胖和房颤状态显著影响。
  • 房颤本身即是HFpEF的强生物标志物,NT-proBNP在房颤伴呼吸困难患者中鉴别价值有限。
  • 按BMI分层的独立纳入和排除阈值可减少误分类,并指导更恰当地使用运动试验。

研究设计与样本

  • 推导队列(n=414)及多中心验证队列1(n=560)、验证队列2(n=207)、非肥胖日本验证队列3(n=77),均以运动导管检查确诊HFpEF或非心源性呼吸困难。
  • 推导的界值在额外验证队列4-6中测试,分别以静息导管检查(n=260)、既往心衰住院(n=447)或运动超声心动图(n=517)诊断HFpEF。

主要发现

  • 现行排除阈值<125 pg/mL在BMI<35 kg/m2时敏感性82%(95%CI 77%-88%),BMI≥35 kg/m2时降至67%(95%CI 58%-77%)。
  • 排除阈值<50 pg/mL在BMI<35 kg/m2时敏感性97%(95%CI 95%-99%),BMI≥35 kg/m2时86%(95%CI 79%-93%);验证队列1和2中分别为91%(95%CI 88%-95%)和86%(95%CI 80%-93%)及80%(95%CI 74%-87%)和84%(95%CI 74%-93%)。
  • 现行共识年龄和BMI分层纳入阈值特异性仅65%(95%CI 57%-72%)。
  • 纳入阈值≥500 pg/mL在BMI<35 kg/m2时特异性85%(95%CI 78%-91%),验证队列中87%(95%CI 80%-94%)和90%(95%CI 81%-99%);BMI≥35 kg/m2时特异性100%,验证队列中93%(95%CI 81%-100%)和100%。
  • BMI≥35 kg/m2时较低纳入阈值≥220 pg/mL特异性88%(95%CI 73%-100%),验证队列中93%(95%CI 81%-100%)和100%;验证队列3-6中<50 pg/mL敏感性93%-98%,≥500 pg/mL特异性82%-89%。

关键数值与推荐

  • 排除阈值<50 pg/mL(敏感性优先),按BMI分层评估。
  • 纳入阈值≥500 pg/mL(特异性优先),BMI≥35 kg/m2时可考虑≥220 pg/mL。

临床怎么用

  • 门诊慢性呼吸困难患者评估HFpEF时,应采用按BMI分层的独立排除和纳入NT-proBNP阈值。
  • BMI≥35 kg/m2患者建议使用更低的排除阈值<50 pg/mL和纳入阈值≥220 pg/mL。
  • 房颤伴呼吸困难患者中NT-proBNP鉴别价值有限,房颤本身提示HFpEF可能,可考虑直接运动试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasma NT-proBNP (N-terminal pro-B-type natriuretic peptide) is commonly used to diagnose heart failure with preserved ejection fraction (HFpEF), but its diagnostic performance in the ambulatory/outpatient setting is unknown because previous studies lacked objective reference standards. METHODS: Among patients with chronic dyspnea, diagnosis of HFpEF or noncardiac dyspnea was determined conclusively by exercise catheterization in a derivation cohort (n=414), multicenter validation cohort 1 (n=560), validation cohort 2 (n=207), and a nonobese Japanese validation cohort 3 (n=77). Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrial fibrillation. Derived cut points were tested in 3 additional validation cohorts (cohorts 4-6) in whom HFpEF was diagnosed by resting catheterization only (n=260), previous hospitalization for heart failure (n=447), or exercise echocardiography (n=517), respectively. RESULTS: Current recommended rule-out NT-proBNP threshold <125 pg/mL had 82% sensitivity (95% CI, 77%-88%) with a body mass index (BMI) <35 kg/m2, decreasing to 67% (95% CI, 58%-77%) with a BMI ≥35 kg/m2. A lower rule-out NT-proBNP threshold <50 pg/mL displayed good sensitivity with a BMI <35 kg/m2 (97% [95% CI, 95%-99%]), with a modest decline in sensitivity with a BMI ≥35 kg/m2 (86% [95% CI, 79%-93%]); diagnostic thresholds were confirmed in validation cohorts 1 and 2 (91% [95% CI, 88%-95%] and 86% [95% CI, 80%-93%] with a BMI <35 kg/m2; 80% [95% CI, 74%-87%] and 84% [95% CI, 74%-93%] with a BMI ≥35 kg/m2). Current consensus age- and BMI-stratified rule-in thresholds demonstrated only 65% specificity (95% CI, 57%-72%). Rule-in NT-proBNP threshold ≥500 pg/mL had 85% specificity (95% CI, 78%-91%) with a BMI <35 kg/m2 (87% [95% CI, 80%-94%] and 90% [95% CI, 81%-99%] in validation cohorts), with 100% specificity at a BMI ≥35 kg/m2 (93% [95% CI, 81%-100%] and 100% in validation cohorts). With a BMI ≥35 kg/m2, lower rule-in thresholds (≥220 pg/mL) provided good specificity (88% [95% CI, 73%-100%]; 93% [95% CI, 81%-100%] and 100% in validation cohorts). Findings were consistent in validation cohorts 3 through 6 (sensitivity of <50 pg/mL, 93%-98%; specificity of ≥500 pg/mL, 82%-89%). NT-proBNP provided no incremental discrimination among patients with history of AF; ≥98% of patients with AF and dyspnea were found to have HFpEF in our cohorts. CONCLUSIONS: In patients with chronic unexplained dyspnea, current rule-in and rule-out NT-proBNP diagnostic thresholds lead to unacceptably high error rates, with important interactions by obesity and AF status. In our study, NT-proBNP provided little value in those with AF and dyspnea because the presence of AF is by itself a robust biomarker of HFpEF. Use of separate rule-in and rule-out diagnostic thresholds stratified by BMI reduces miscategorization and can guide more appropriate use of exercise testing for possible HFpEF.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Reddy, Tada, Obokata, et al. Evidence-Based Application of Natriuretic Peptides in the Evaluation of Chronic Heart Failure With Preserved Ejection Fraction in the Ambulatory Outpatient Setting. Circulation. 2025. PMID: 39840432. doi:10.1161/CIRCULATIONAHA.124.072156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。